-5%
Daprodustat belongs to the class of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). It works by regulating intracellular levels of hypoxia-inducible factor (HIF), a transcription factor involved in erythropoiesis.
By reversibly inhibiting HIF-prolyl hydroxylase enzymes, daprodustat stimulates the body’s natural response to low oxygen levels. This leads to:
- Increased production of endogenous erythropoietin (EPO)
- Improved regulation of iron transport proteins
- Reduced hepcidin levels, enhancing iron availability
- Increased hemoglobin synthesis and red blood cell production
These combined effects help improve anemia in patients with CKD.
Aprodust is prescribed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients who have been undergoing dialysis for at least four months.
Aprodust is not intended for:
- Replacing red blood cell transfusions when rapid correction of anemia is necessary.
- Treating anemia in CKD patients who are not receiving dialysis.